Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Market Closed - Japan Exchange Other stock markets 01:30:00 2025-12-05 EST			5-day change	1st Jan Change
4,410.00 ^JPY	-1.41%		-2.13%	+5.48%

12-05	Nikkei Falls Amid Caution Ahead of U.S. Inflation Data, Bond Yields Surge	MT
12-04	Innovent Biologics Closes Takeda Partnership, Issues New Shares	MT

Transcript : Takeda Pharmaceutical Company Limited, 2024 Earnings Call, May 09, 2024

Published on 05/09/2024 at 06:00 am EDT

S&P Capital IQ

Presenter Speech
Christopher David O'Reilly (Executives)

Thank you very much for your participation in the conference call for the financial results for fiscal year 2023 of Takeda Pharmaceutical

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Takeda Pharmaceutical Company Limited

12-05	Nikkei Falls Amid Caution Ahead of U.S. Inflation Data, Bond Yields Surge	MT
12-04	Innovent Biologics Closes Takeda Partnership, Issues New Shares	MT
11-21	Takeda pharmaceutical conducted thorough assessment, found there was no confirmed causal relationship to use of Adzynma & patient death - spokesperson	RE
11-21	Takeda Pharmaceuticals' Drug Adzynma Under FDA Investigation Related to Patient Death	DJ
11-21	Fda investigates death linked to Adzynma treatment for congenital thrombotic thrombocytopenic purpura	RE
11-21	Takeda Pharmaceutical's Adzynma Under US FDA Probe Following Death of Pediatric Patient	MT
11-13	Beacon Biosignals raises $86 million to accelerate AI-driven insights into brain health	RE
11-12	Alkermes shares tumble as sleep disorder drug shows limited advantage over rival	RE
11-11	Beacon Biosignals, Inc. announced that it has received $86 million in funding from a group of investors	CI
11-11	Neurocrine Biosciences' Depressive Disorder Drug Fails to Meet Primary Goal in Phase 2 Study	MT
11-07	Takeda Presents New Data Showing Mezagitamab Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy	CI
11-06	US FDA awards six more fast-track vouchers to speed drug reviews	RE
11-03	Takeda Inc. Announces Completion of the 7-Year Pivotal Phase 3 Tides Trial Evaluating Its Dengue Vaccine, Qdenga®?V	CI
10-30	Asian Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading	MT
10-30	Takeda Pharmaceutical Company Limited, Q2 2026 Earnings Call, Oct 30, 2025
10-30	Takeda Pharmaceutical Company Limited Declares Dividend for Second Quarter-End of Fiscal Year Ending March 31, 2026, Payable on December 1, 2025	CI
10-30	Takeda Pharmaceutical Attributable Profit Falls 40% in Fiscal H1	MT
10-30	Takeda Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended September 30, 2025	CI
10-30	Takeda Pharmaceutical's Fiscal Q2 Core Earnings, Revenue Decline; Fiscal 2025 Outlook Trimmed	MT
10-30	Takeda Swings to Loss on Impairment Charges, Cuts Guidance -- Update	DJ
10-30	Takeda Pharmaceutical Company Limited Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026	CI
10-30	Takeda Posts Quarterly Net Loss, Cuts Guidance	DJ
10-27	Takeda Inc. Announces the Recently FDA- Approved Hyhub and Hyhub Duo Devices Now Available in the U.S. to Simplify Hyqvia® Infusion Preparation	CI
10-27	HyHub(tm) and HyHub(tm) Duo devices now available in the U.S. to simplify HYQVIA® infusion preparation	RE
10-22	Innovent Biologics, Inc., Takeda Pharmaceutical Company Limited - Special Call